Fig. 4
From: TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
Enzalutamide inhibits androgen biosynthetic enzyme expression in bone tumors. a Westernblot analysis of VCaP scr shRNA and VCaP ERG shRNA tumors. b Quantitation of ERG, AR, AKR1C3, HSD3B1 and HSD3B2 in bone tumors
